Institutional Cluster

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago
Institutional cluster: 5 buyers, 1 sellers (bullish)
Actionable Insight • Neutral

This cluster is dominated by passive-index rebalancing (4 of 5 buyers are mega-passive), not active fundamental conviction — treat the signal as low conviction. With 92% analyst buy-rating but no active-hedge-fund buyers and historical T+20 calls on CRVS averaging -19% returns, the cluster alone does not warrant position entry. Wait for a catalyst-linked active buyer or an actionable catalyst filing before acting.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
CRVS ▲ +24.05% at T+60d
NEUTRAL call ✓ call won +24.05% · α vs SPY +19.66% · entry $11.60 → $14.39
Entry anchored
Jun 11, 10:52 AM ET
via exchange tick
T+1d
+2.84%
call +2.84% · α +2.30%
$11.93
settled 4mo ago
T+5d
+3.45%
call +3.45% · α +3.01%
$12.00
settled 4mo ago
T+20d
+39.66%
call +39.66% · α +37.76%
$16.20
settled 3mo ago
T+60d
+24.05%
call +24.05% · α +19.66%
$14.39
settled 24d ago

Executive Summary

An institutional cluster formed in CRVS during 2025-Q3, with five institutions — including State Street, Fidelity, and Wellington — adding positions totaling $6.7M in net buying, while only Morgan Stanley trimmed its position. The buying is heavily concentrated in mega-passive funds, suggesting the cluster likely reflects index rebalancing or passive inflows rather than an active fundamental thesis, and historical model reads on CRVS have been severely negative (0% win rate at T+20, -19% avg return).

Key Financial Metrics

Direction
accumulating
Buy Value
$10.2M
Sell Value
$3.6M
Net Flow
$6.7M

Institutional Positions

Net institutional flow: $6.7M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
State StreetADD+51.4%$7.4M$4.8M
FidelityDOUBLED+529.1%$11.0K$10.0K
Wells FargoADD+34.4%$268.0K$160.0K
UBSADD+80.7%$1.2M$836.0K
Wellington Management GroupADD+76%$1.3M$919.0K

▼ Sellers (1)

InstitutionActionChangePrev ValueValue Δ
Morgan StanleyTRIM-31%$3.6M$971.0K

Key Facts

  • 5 institutional buyers added a net $6.7M in CRVS during Q3 2025
  • 4 of 5 buyers are mega-passive funds (State Street, Fidelity, Wells Fargo, UBS); only Wellington is an active asset manager
  • State Street alone added $4.8M, accounting for most of the net buying
  • Morgan Stanley trimmed 31% of shares but raw value increased due to share price appreciation
  • Historical CRVS reports show 0% win rate at T+20 across 8 settled reports, with avg return -19%
  • Ticker has 92% analyst buy/strong-buy rating and $938M market cap

Financial Impact

Institutional buyers added $6.7M in new holdings while one seller trimmed $971K in value (though dollar amount rose due to price), for net institutional accumulation of approximately $5.7M.

institutional ownership increasenet share accumulation

Risk Factors

  • 45-day 13F reporting lag — positions as of Sep 30, 2025 may have been fully unwound
  • Passive-dominated buying → no active fundamental thesis to trade against
  • Historical model reads on CRVS have 0% T+20 win rate; cluster patterns alone likely insufficient to overcome this

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-CRVS-2025-Q3
9 reports for CRVS
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+1▲ +2.61%Mar 12, 2026
Filters
Rows
Reports for CRVS — sortable, filterable
TypeNow
Aug 21, 2026
6w ago
Institutional Cluster
BULLISH ★ 6/10
$14.46 $12.42▼ −14.11%▼ −13.58%—
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$13.68 $14.33▲ +4.75%▲ +1.44%—
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$11.60 $16.20▲ +39.66%▲ +37.76%—
May 14, 2026
20w ago
8-K
BULLISH ★ 7/10
$13.66 $11.93▼ −12.63%▼ −11.77%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$15.55 $11.12▼ −28.49%▼ −28.51%—
Apr 24, 2026
23w ago
DEFA14A
NEUTRAL ★ 4/10
$15.92 $12.83▼ −19.41%▼ −24.37%—
Apr 21, 2026
23w ago
Press Release
NEUTRAL ★ 4/10
$17.14 $12.21▼ −28.76%▼ −33.68%—
Mar 12, 2026
29w ago
Press Release
BULLISH ★ 8/10
$15.32 $15.17▼ −0.98%▼ −4.57%—
Mar 5, 2026
30w ago
Press Release
NEUTRAL ★ 3/10
$15.80 $14.71▼ −6.87%▼ −4.82%—
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (65h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 11, 2026